Acute on Chronic Liver Failure
Nov
2026
Description
This session presents new data on predicting and managing acute-on-chronic liver failure (ACLF), covering updated diagnostic criteria, mortality risk in critically ill cirrhotic patients, and management of variceal bleeding and bloodstream infections in this population.
Presentations
5:00 PM
- 5:15 PM
Convention Center - Bluebird Ballroom 1C
Soluble Programmed Death Ligand 1 Outperforms Interleukin 6, Urinary Neutrophil Gelatinase-Associated Lipocalin, and Neutrophil-to-Lymphocyte Ratio for ACLF Prediction in Patients with Cirrhosis: The LiverHope Biomarker Study.
María MM Moreta, MD | Abstract Presenter
5:15 PM
- 5:30 PM
Convention Center - Bluebird Ballroom 1C
Low-Dose Continuous Terlipressin: Comparable Efficacy, Lower Toxicity in ACLF Variceal Bleeding
Khushboo Yadav, MD | Abstract Presenter
5:30 PM
- 5:45 PM
Convention Center - Bluebird Ballroom 1C
Bloodstream Infection Phenotypes and Resistance Patterns among Patients with Cirrhosis Hospitalized with Acute-on-Chronic Liver Failure
Timothy McAuliffe, MD | Abstract Presenter
5:45 PM
- 6:00 PM
Convention Center - Bluebird Ballroom 1C
Chronic kidney disease and mortality in critically ill patients with decompensated cirrhosis
Rahul R Thakkar, MD | Abstract Presenter
6:00 PM
- 6:15 PM
Convention Center - Bluebird Ballroom 1C
Early Deep Sedation Is Associated with Increased Mortality in Mechanically Ventilated Patients with Cirrhosis
Benjamin E Rosenthal, MD | Abstract Presenter
6:15 PM
- 6:30 PM
Convention Center - Bluebird Ballroom 1C
Pragmatic definition of ACLF using global harmonization predicts mortality with increasing grades across three large patient cohorts.
Jasmohan S. Bajaj, MD, FAASLD | Abstract Presenter
